FEB 25, 2008 - 17:19 ET
Axcan Announces Completion of Transaction With TPG Capital
MONT-SAINT-HILAIRE, QUEBEC--(Marketwire - Feb. 25, 2008) - Axcan Pharma Inc. ("Axcan" or "the Company") today announced the completion of the transaction in which all of the common shares of Axcan have been acquired by an affiliate of TPG Capital ("TPG").
Under the terms of the agreement, Axcan shareholders are entitled to receive U.S. $23.35 in cash for each share of Axcan common stock held. As a result, Axcan common stock will cease trading on the NASDAQ Global Market and on the Toronto Stock Exchange at market close on Monday, February 25, 2008, and will no longer be listed on these stock exchanges.
Payment of the cash consideration will be made by Computershare Investor Services, which serves as paying agent.
Axcan stockholders who possess physical stock certificates have received instructions and a letter of transmittal by mail from Computershare Investor Services concerning how and where to forward their certificates for payment. For shares held in "street name" by a broker, bank or other nominee, shareholders will not need to take any action to have shares converted into cash, as this will be carried out by the broker, bank or other nominee. Questions about the payment of merger proceeds should be directed to the appropriate broker, bank or other nominee.
ABOUT AXCAN PHARMA
Axcan is a leading multinational specialty pharmaceutical company focused on gastroenterology. The Company develops and markets a broad line of prescription products to treat a range of gastrointestinal diseases and disorders such as inflammatory bowel disease, irritable bowel syndrome, cholestatic liver diseases and complications related to pancreatic insufficiency. Axcan's products are marketed by its own specialized sales forces in North America and the European Union and through commercial collaborations in many markets around the world.
TPG is a leading private investment firm founded in 1992, with more than $35 billion of assets under management and offices in San Francisco, London, Hong Kong, New York, Minneapolis, Fort Worth, Melbourne, Menlo Park, Moscow, Mumbai, Beijing, Shanghai, Singapore and Tokyo. TPG has extensive experience with global public and private investments executed through leveraged buyouts, recapitalizations, spinouts, joint ventures and restructurings. Please visit www.tpg.com
FOR FURTHER INFORMATION PLEASE CONTACT:
Axcan Pharma Inc.
Senior Director, Investor Relations and Communications
450-467-2600 ext. 2000